

め、病院であれば研究が可能である。また、マーカーが開発された際には、発展途上国でも対応できる可能性がある。

#### 文 献

- 1) Adolfsson, R., Gottfries, C.G., Roos, B.E. et al.: Post-mortem distribution of dopamine and homovanillic acid in human brain, variations related to age, and a review of the literature. *J. Neural. Transm.*, 45; 81-105, 1979.
- 2) Blennow, K., Hampel, H., Weiner, M. et al.: Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. *Nat. Rev. Neurol.*, 6; 131-144, 2010.
- 3) Laruelle, M., Abi-Dargham, A., van Dyck, C.H. et al.: Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects. *Proc. Natl. Acad. Sci. USA*, 93; 9235-9240, 1996.
- 4) McGowan, S., Lawrence, A.D., Sales, T. et al.: Presynaptic dopaminergic dysfunction in schizophrenia: a positron emission tomographic [18F] fluorodopa study. *Arch. Gen. Psychiatry*, 61; 134-142, 2004.
- 5) Straus, S.E., Thorpe, K.E. and Holroyd-Leduc, J.: How do I perform a lumbar puncture and analyze the results to diagnose bacterial meningitis? *JAMA*, 296; 2012-2022, 2006.
- 6) Wester, P., Bergström, U., Eriksson, A. et al.: Ventricular cerebrospinal fluid monoamine transmitter and metabolite concentrations reflect human brain neurochemistry in autopsy cases. *J. Neurochem.*, 54; 1148-1156, 1990.
- 7) Williams, H.J., Owen, M.J. and O'Donovan, M.C.: Is COMT a Susceptibility Gene for Schizophrenia? *Schizophr. Bull.*, 33; 635-641, 2007.

#### ● 特集論文公募のお知らせ ●

「精神科治療学」では特集への論文を公募しています。ご投稿をお待ちしております。

第27巻3号特集(2012年3月発行)

精神科臨床における「頭部外傷  
後遺症」の評価とマネジメント

締切: 2012年1月14日必着

第27巻4号特集(2012年4月発行)

正常との境界域を診る

締切: 2012年1月27日必着

- ・特集への応募論文は、投稿規定の枠内で公募いたします(体裁は投稿規定をご参照下さい)。
- ・ご投稿の論文は編集委員会にて審査の上、結果をご通知いたします。お問い合わせは下記まで。  
〒168-0074 東京都杉並区上高井戸1-2-5 ☎03-3329-0033 (株)星和書店「精神科治療学」編集部

# Analyses of Fyn-tyrosine kinase and NMDA-R in the post-mortem brains of schizophrenia

Hattori K, Tanaka H, Wakabayashi C, Uchiyama H, Yamamoto N, Hori H, Teraishi T, Sasayama D, Kunugi H

Dept Mental Disorder Research, National Inst Neurosci, Nat Center Neurol & Psychiatry, Japan

## Summary

- Fyn's function: Learning, LTP, dopamine signaling
- Fyn's substrate: GRIN2B (NMDA-R subunit)
- Evaluation of Fyn, NMDA-R in Schizo brain


Main findings	Schizo brain
Fyn, Fyn activity	Increased
GRIN1	Unchanged
GRIN2A & 2B	Decreased

- GRIN2A & 2B reduction: Might reflect NMDA-R hypofunction, decreased synapses in Schizophrenia

## Introduction

Fyn kinase is a key mediator of the crosstalk between D2-R and NMDA-R

Features of Fyn-deficient mice





Hattori et al., JBC, 2006




- Deficits in LTP, cognition
- Defective maternal behavior
- Fearful
- Lower sensitivity to ethanol
- Lower sensitivity to haloperidol

## Method

Preparation of Fyn-ELISA



Preparation of Dot-blot



Sample

Stanley Neuropathology Consortium (BA6)


Sampl	Nos
Bipolar	15
Dep	15
Control	15
Schizo	15

Blind analyses


Unicode after data submission

## Results

Fyn sandwich ELISA



Active-form Fyn




Other results


- No difference among diagnostic groups in the mRNA levels of fyn, GRIN1, GRIN2A or GRIN2B.
- Risperidone treatment did not affect GRIN1, GRIN2A or GRIN2B protein levels in the frontal cortices of mice.

Acknowledgements

Postmortem brain tissue was donated by The Stanley Medical Research Institute



## Discussion



•The GRIN2A/2B reduction might be the cause of NMDA-R hypofunction, which has been hypothesized in schizophrenia pathophysiology.

•Increased Fyn might be a result of antipsychotic treatment or a compensatory consequence of reduced NMDA-R function.

•Analyses using larger sample size are now underway.

# Analyses of monoamine metabolites in the cerebrospinal fluid of patients with schizophrenia and depression

Hattori K, Sasayama D, Teraishi T, Fujii T, Tanaka H, Kunugi H

Department of Mental Disorder Research, National Institute of Neuroscience, National Center Hospital of Neurology and Psychiatry, Japan


## Summary

•We evaluated the levels of monoamine metabolites in the CSF of patients with schizophrenia and depression.

	HVA	MHPG	5-HIAA	These changes supposed to be the effect of medication
Schizophrenia	↑	→	→	
Depression	→	↓	↓	

- Among the schizophrenic patients, higher HVA → lower positive symptoms, higher 5-HIAA/MHPG → higher negative symptoms severer side effects (EPS)
- CSF monoamine levels could be used as biomarkers for response to antipsychotic medication.

## Introduction



•Monoamine neurotransmitters play crucial roles in psychiatric disorders. The levels of monoamine metabolites, i.e., HVA, MHPG and 5-HIAA in the cerebrospinal fluid (CSF), reflect the release of dopamine, noradrenalin and serotonin respectively in the brain.  
•This study was aimed to examine the possible use of CSF monoamine metabolites as biomarkers for schizophrenia and depression.

## Method

### Subjects

- Patients: Consensus diagnosis by 2 psychiatrists (DSM-IV)
- Controls: Recruited through advertisements in free local magazines and our website.
- Past history were ruled out by Mini-International Neuropsychiatric Interview.

	No.
Schizophrenia	35
Depression	35
Control	32
Total	102

All patients were medicated.



### Lumbar puncture

- Lateral position, L4/5
- With local anesthesia



### Psychiatric assessments


- Schizophrenia: PANSS
- Depression: HDRS
- Side effect: DIEPSS

### Analyses of CSF HVA, MHPG and 5-HIAA levels.


The levels of monoamine metabolites were analyzed by high performance liquid chromatography (HPLC) by SRL Inc. (Medical laboratory testing company)

### Neurological assessments




- Jolt accentuation
- Ophthalmoscopy: Papillary edema, Pulse of central retinal vein



## Results




### Positive symptom (PANSS)




- 5-HIAA / MHPG levels did not differ between schizophrenia and the controls.
- 5-HIAA / MHPG levels were significantly decreased in depression.
- Among schizophrenic group, 5-HIAA / MHPG levels correlated with negative symptoms or severer extra pyramidal symptoms.


### Negative symptom and 5-HIAA / MHPG



### EPS side effect and 5-HIAA / MHPG



## Discussion




•Most previous studies on CSF HVA levels in unmedicated schizophrenic patients reported no significant difference between patients and controls.  
•Several studies showed that the HVA levels increased after antipsychotic medication.  
→ The enhanced CSF HVA levels in our schizophrenic patients supposed to be the effect of antipsychotic medication. (Left figure).  
•Similarly, most previous studies on CSF 5-HIAA levels in unmedicated depression reported no significant difference between patients and controls, and the 5-HIAA levels increased after antidepressant medication. Therefore, reduced 5-HIAA levels in the depression could be due to medication.  
•Correlations of monoamine levels with symptoms and adverse effects in the schizophrenia patients suggest that the CSF monoamine levels could be used as biomarkers for response to antipsychotic medication.

### 気分障害CSF中アミン代謝産物の解析

国立精神・神経医療研究センター  
神経研究所 疾病研究第3部

○服部功太郎, 篠山大明, 寺石俊也, 吉田寿美子, 功刀浩

### アミン系伝達物質の代謝経路



### 対象

- 統合失調症 } 院内ポスター
- 気分障害 } 主治医からの紹介
- 健常対照 → フリーペーパー  
インターネット

### 精神科的診察

- M.I.N.Iにて診断
- 症状評価: PANSS, HAM-D
- 副作用: DIEPSS

### 腰椎穿刺

#### 安全性の確保

- 髄膜兆候等の除外
- 眼底検査(拍動確認)

#### 苦痛の軽減

- 十分な麻酔
- 痛みは採血と同等

#### 有害事象への対応

- 24時間電話対応
- 医療補償



### 検体収集状況

	検体数 症例数	
統合失調症	56	38
気分障害	47	42
健常対照	44	40
その他	3	3
Total	150	121

### 結果

